37 cases on record
- Cases on record
- 37
- As claimant
- 3
- As respondent
- 34
- Patents held
- Not recorded
- Core tech
- Not recorded
| Case no. | Parties | Role | Court | Filed | Duration | Outcome |
|---|---|---|---|---|---|---|
| 2:26-cv-02929 | Xeris Pharmaceuticals, Inc. v. Sandoz, Inc. | Defendant | D.N.J. | 20 Mar 2026 | 80 d | Case Consolidated |
| 1:26-cv-00232 | Otsuka Pharmaceutical Co., Ltd. v. Sandoz, Inc. | Defendant | D. Del. | 5 Mar 2026 | 41 d | Dismissed without Prejudice |
| 2:25-cv-16878 | Celgene, Corp. v. Sandoz, Inc. | Defendant | D.N.J. | 23 Oct 2025 | 25 d | Consent Judgment |
| 2:25-cv-03986 | Aurinia Pharmaceuticals, Inc. v. Sandoz, Inc. | Defendant | D.N.J. | 8 May 2025 | 209 d | Case Consolidated |
| 2:25-cv-01167 | Bausch & Lomb, Inc. v. Sandoz, Inc. | Defendant | D.N.J. | 11 Feb 2025 | 400 d | Dismissed without Prejudice |
| 3:25-cv-00231 | AstraZeneca AB v. Sandoz, Inc. | Defendant | D.N.J. | 9 Jan 2025 | 148 d | Case Consolidated |
| 3:24-cv-10627 | AstraZeneca AB v. Sandoz, Inc. | Defendant | D.N.J. | 20 Nov 2024 | 524 d | Consent Judgment |
| 1:24-cv-01244 | Pfizer, Inc. v. Sandoz, Inc. | Defendant | D. Del. | 12 Nov 2024 | 218 d | Dismissed without Prejudice |
| 3:24-cv-10239 | Intra-cellular Therapies, Inc. v. Sandoz, Inc. | Defendant | D.N.J. | 1 Nov 2024 | 70 d | Case Consolidated |
| 1:24-cv-01192 | Sandoz, Inc. v. Boehringer-Ingelheim | Plaintiff | D. Del. | 24 Oct 2024 | 148 d | Judgment on the merits for Plaintiff |
| 1:24-cv-00085 | Regeneron Pharmaceuticals, Inc. v. Sandoz, Inc. | Defendant | N.D. W. Va. | 13 Sep 2024 | 361 d | Dismissed without Prejudice |
| 3:24-cv-08855 | Intra-cellular Therapies, Inc. v. Sandoz, Inc. | Defendant | D.N.J. | 29 Aug 2024 | 589 d | Case Consolidated |
| 3:24-cv-08164 | AstraZeneca AB v. Sandoz, Inc. | Defendant | D.N.J. | 31 Jul 2024 | 636 d | Consent Judgment |
| 3:24-cv-05889 | AstraZeneca AB v. Sandoz, Inc. | Defendant | D.N.J. | 7 May 2024 | 24 d | Case Consolidated |
| 3:24-cv-04327 | Intra-cellular Therapies, Inc. v. Sandoz, Inc. | Defendant | D.N.J. | 28 Mar 2024 | 130 d | Case Consolidated |
| 3:24-cv-01972 | Beigene USA, Inc. v. Sandoz, Inc. | Defendant | D.N.J. | 8 Mar 2024 | 160 d | Dismissed without Prejudice |
| 3:24-cv-00641 | AstraZeneca AB v. Sandoz, Inc. | Defendant | D.N.J. | 2 Feb 2024 | 119 d | Case Consolidated |
| 24-1078 | Sandoz, Inc. v. Duke University | Plaintiff | Fed. Cir. | 25 Oct 2023 | 755 d | Case Reversed |
| 1:23-cv-01191 | ZS Pharma, Inc. v. Sandoz, Inc. | Defendant | D. Del. | 20 Oct 2023 | 334 d | Consent Judgment |
| 23-2264 | Sandoz, Inc. v. Sanofi | Plaintiff | Fed. Cir. | 10 Aug 2023 | 57 d | Voluntary dismissal |
| 23-2063 | Astellas Pharma, Inc. v. Sandoz, Inc. | Defendant | Fed. Cir. | 23 Jun 2023 | 453 d | Vacated and Remanded |
| 23-2032 | Astellas Pharma, Inc. v. Sandoz, Inc. | Defendant | Fed. Cir. | 16 Jun 2023 | 460 d | Vacated and Remanded |
| 1:23-cv-00597 | Janssen Pharmaceuticals, Inc. v. Sandoz, Inc. | Defendant | D. Del. | 31 May 2023 | 77 d | Voluntary dismissal |
| 1:23-cv-02943 | Janssen Pharmaceuticals, Inc. v. Sandoz, Inc. | Defendant | D.N.J. | 30 May 2023 | 134 d | Case Consolidated |
| 1:23-cv-02406 | Amgen, Inc. v. Sandoz, Inc. | Defendant | D.N.J. | 1 May 2023 | 374 d | Injunction Granted |
| 2:23-cv-01214 | Astellas Pharma, Inc. v. Sandoz, Inc. | Defendant | D.N.J. | 2 Mar 2023 | 722 d | Dismissed without Prejudice |
| 1:22-cv-01316 | Array BioPharma, Inc. v. Sandoz, Inc. | Defendant | D. Del. | 6 Oct 2022 | 826 d | Dismissed without Prejudice |
| 1:22-cv-01124 | Neurocrine Biosciences, Inc. v. Sandoz, Inc. | Defendant | D. Del. | 26 Aug 2022 | 405 d | Dismissed without Prejudice |
| 1:22-cv-01101 | ZS Pharma, Inc. v. Sandoz, Inc. | Defendant | D. Del. | 22 Aug 2022 | 758 d | Consent Judgment |
| 1:22-cv-00164 | Acerta Pharma B.V. v. Sandoz, Inc. | Defendant | D. Del. | 4 Feb 2022 | 774 d | Consent Judgment |
| 22-1194 | Lundbeck, Ltd. v. Sandoz, Inc. | Defendant | Fed. Cir. | 29 Nov 2021 | 738 d | Appeal Dismissed |
| 22-1151 | Amgen, Inc. v. Sandoz, Inc. | Defendant | Fed. Cir. | 15 Nov 2021 | 520 d | Appeal Dismissed |
| 22-1149 | Amgen, Inc. v. Sandoz, Inc. | Defendant | Fed. Cir. | 12 Nov 2021 | 523 d | Appeal Dismissed |
| 1:21-cv-00664 | Astellas Pharma, Inc. v. Sandoz, Inc. | Defendant | D. Del. | 7 May 2021 | 1823 d | Judgment on the merits for Defendant |
| 1:20-cv-01589 | Astellas Pharma, Inc. v. Sandoz, Inc. | Defendant | D. Del. | 24 Nov 2020 | 927 d | Judgment on the merits for Defendant |
| 1:18-cv-00997 | Duke University v. Sandoz, Inc. | Defendant | D. Colo. | 26 Apr 2018 | 2973 d | Judgment on the merits for Defendant |
| T-1831-22|T-1842-22 | Boehringer Ingelheim (canada) Ltd v. Sandoz, Inc. | Defendant | Canada Federal court | – | Judgment on the merits for Defendant |
Source: Patsnap Litigation Data. Cases naming Sandoz, Inc. in the current snapshot.
Run this in Eureka
Patsnap Eureka
See what Sandoz is protecting
Portfolio, claim scope and where its coverage is thin. Every answer cites the records behind it.
Analyse this portfolio10,000 free credits to start
Sandoz
Map this dispute space
- 01Ranked prior artEvery hit source-linked
- 02Claim-level comparisonAgainst your own product
- 03Legal statusAcross 174 jurisdictions
Disclaimer. This page indexes publicly available court docket data and is provided for general information and reference only. It is not legal advice and must not be relied upon as such.
Coverage has limits. Records come from a snapshot and may lag live dockets. Sealed filings, amended complaints and post-closure motions may not be reflected, and a case missing from this list is not evidence that it does not exist. Counts on this page describe what the snapshot contains, nothing more.
No characterisation of any party. Appearing on this page means a party is named in a docket record. Nothing here should be read as an assertion that any party infringed, that any patent is valid or invalid, or that any party prevailed.